Neurocrine Biosciences, Inc.

Other

Janssen Pharmaceutica Nv

Charles Q Huang

James R McCarthy

Chen Chen

Zhiqiang Guo

Yongsheng Chen

Mustapha Haddach

Warren Stanfield Wade

Keith M Wilcoxen

Jaimie Karyn Rueter

Fabio C Tucci

Dongpei Wu

Wesley J Dwight

Jeffrey Paul Whitten

Ronald L Wolin

Martin W Rowbottom

Timothy W Lovenberg

Dominic P Behan

Brian Dyck

Yun-Fei Zhu

Terence J Moran

Alejandro Santillán, Jr

Thomas R Webb

Collin Regan

Liu Y Tang

Jodie Nelson

Philip E Erickson

Marion Lanier

Mustapha Hadduch

The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.

Aryl piperidine amides

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, R, R, Rand X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Gonadotropin-releasing hormone receptor antagonists and methods related thereto

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein n, R, R, R, R, R, R, R, R, Rand X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein Ris NRRor OR; Ris Calkyl, Calkyloxy or Calkylthio; Ris hydrogen, Calkyl, Calkylsulfonyl, Calkylsulfoxy or Calkylthio; Ris hydrogen, Calkyl, mono- or di(Ccycloalkyl)methyl, Ccycloalkyl, Calkenyl, hydroxyCalkyl, CalkylcarbonyloxyCalkyl or CalkyloxyCalkyl; Ris Calkyl, mono- or di(Ccycloalkyl)methyl, ACH, CalkyloxyCalkyl, hydroxyCalkyl, Calkenyl, thienylmethyl, furanylmethyl, CalkylthioCalkyl, morpholinyl, mono- or di(Calkyl)aminoCalkyl, di(Calkyl)amino, CalkylcarbonylCalkyl, Calkyl substituted with imidazolyl; or a radical of formula &#x2014;Alk&#x2014;O&#x2014;CO&#x2014;Ar; or Rand Rtaken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).

Pyrazolopyrimidines as CRF receptor antagonists

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:wherein n, R, R, R, R, R, R, R, R, Rand X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke.

CRF receptor antagonists and methods relating thereto

CRF antagonistic pyrazolo&lsqb;4,3-b&rsqb;pyridines

CRF antagonistic quino-and quinazolines

Growing community of inventors

San Diego, CA, United States of America

Charles Q Huang